Health and Fitness Health and Fitness
Thu, October 13, 2011
[ Thu, Oct 13th 2011 ] - Market Wire
Critical Outcome Technologies Inc. Receives U.S. Patent for Promising Oncology Compound COTI-2
[ Thu, Oct 13th 2011 ] - Market Wire
Fifth Record-Breaking Quarter for Diligent Board Member Services
[ Thu, Oct 13th 2011 ] - Market Wire
Edison Expands Oncology Sector Presence with Laun .. h of Research Coverage on Sunesis Pharmaceuticals
[ Thu, Oct 13th 2011 ] - Market Wire
OPKO Health Announces Acquisition of Claros Diagnostics
[ Thu, Oct 13th 2011 ] - Market Wire
Cerus to Release Third Quarter 2011 Results on November 1, 2011
[ Thu, Oct 13th 2011 ] - Market Wire
InSite Vision to Present at the Newsmakers in the Biotech Industry Conference
[ Thu, Oct 13th 2011 ] - Market Wire
TheraBiogen, Inc. Begins Record Shipment of Its T .. Cold and Flu Relief to National Drug Store Chains
[ Thu, Oct 13th 2011 ] - Market Wire
Daxor Corporation Announces Signed Trial Agreemen .. iovascular Consultants PLLC in San Antonio, Texas
[ Thu, Oct 13th 2011 ] - Market Wire
Amica Mature Lifestyles to Announce First Quarter .. esults and Host Conference Call November 14, 2011
[ Thu, Oct 13th 2011 ] - Market Wire
High Growth Biotech Firms Zalicus and Sequenom Ready for Knockout Fourth Quarter
[ Thu, Oct 13th 2011 ] - Market Wire
Strong Pipelines From Allos Therapeutics and Dynavax Tech Poised to Pay Off
[ Thu, Oct 13th 2011 ] - Market Wire
Mercka?s ISENTRESS® (raltegravir) in Combination .. cal and Immunological Efficacy Versus the Efavire
[ Thu, Oct 13th 2011 ] - Market Wire
Synageva BioPharma and Trimeris Announce Special Meetings of Stockholders to Approve Merger
[ Thu, Oct 13th 2011 ] - Market Wire
AMRI Appoints New President, India Operations and .. of Project Management a" Pharmaceutical Services
[ Thu, Oct 13th 2011 ] - Market Wire
Vanguard Health Systems Appoints Former Tennessee Governor to Board of Directors
[ Thu, Oct 13th 2011 ] - Market Wire
Horizon Pharma Receives U.S. Patent Allowance for DUEXIS(R) in the United States
[ Thu, Oct 13th 2011 ] - Market Wire
Micromet Obtains FDA Feedback on Registration Strategy for Blinatumomab in Relapsed/Refractory ALL
[ Thu, Oct 13th 2011 ] - Market Wire
POZEN Reports Top-Line Data from Long-Term Safety Study of PA32540
[ Thu, Oct 13th 2011 ] - Market Wire
Galectin Therapeutics to Announce New Data on the Treatment of Fatty Liver Disease and Fibrosis
[ Thu, Oct 13th 2011 ] - Market Wire
U.S. Sales of EGRIFTA(R) Driving Revenue Growth
[ Thu, Oct 13th 2011 ] - Market Wire
Los datos presentados durante el 5 Congreso trien .. or ECTRIMS y ACTRIMS demuestran el compromiso y l
[ Thu, Oct 13th 2011 ] - Market Wire
ISTA Pharmaceuticals Announces Statistically Significant Phase 3 Results for PROLENSA(TM)
[ Thu, Oct 13th 2011 ] - Market Wire
ISTA Pharmaceuticals Reports Results From the Sec .. URA(TM) Phase 3 Clinical Program for Dry Eye Dise
[ Thu, Oct 13th 2011 ] - Market Wire
China Medical Technologies Receives SFDA Approval .. ed KRAS Assay for Colorectal Cancer Targeted Drug
Wed, October 12, 2011
[ Wed, Oct 12th 2011 ] - Market Wire
Financial Statement 10/11
[ Wed, Oct 12th 2011 ] - Market Wire
Neue Daten, die auf dem 5. gemeinsamen Kongress v .. tellt werden, zeigen neue Forschungsanstze von Bi
[ Wed, Oct 12th 2011 ] - Market Wire
Cumberland Pharmaceuticals Appoints Rick S. Greene Chief Financial Officer
[ Wed, Oct 12th 2011 ] - Market Wire
Savient Pharmaceuticals to Hold Third Quarter 201 .. lts Conference Call on Thursday, November 3, 2011
[ Wed, Oct 12th 2011 ] - Market Wire
Helix BioPharma Corp. Files IND Clinical Hold Res .. d Topical Interferon Alpha-2b Phase II/III Effica
[ Wed, Oct 12th 2011 ] - Market Wire
Mylan Announces Intention to Refinance Existing Secured Credit Facility

Mylan Announces Intention to Refinance Existing Secured Credit Facility


Published on 2011-10-12 19:00:27 - Market Wire
  Print publication without navigation


Mylan Announces Intention to Refinance Existing Secured Credit Facility -- PITTSBURGH, Oct. 12, 2011 /PRNewswire/ --

Mylan Announces Intention to Refinance Existing Secured Credit Facility

[ ]

PITTSBURGH, Oct. 12, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: [ MYL ]) today announced that it intends to refinance its existing secured credit facility. The proposed $2.25 billion facility is expected to be comprised of a $1 billion revolving credit facility and a $1.25 billion Term Loan A.  The facility will have a five year term and include customary terms and covenants. The facility is expected to close in November 2011, subject to market and other customary conditions.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit [ www.mylan.com ]. For more information about generic drugs, please visit [ www.ChoosingGenerics.com ].

SOURCE Mylan Inc.

[ Back to top ]

RELATED LINKS
[ http://www.mylan.com ]

Contributing Sources